tbuckley/cabot-search huggingface dataset:
NCOG-16. THE IMPACT OF THE TIMING OF HEALTH-RELATED QUALITY OF LIFE ASSESSMENTS ON THE ACTUAL RESULTS IN GLIOMA PATIENTS: A RANDOMIZED PROSPECTIVE STUDY
Authors: Marthe Peeters, Hanneke Zwinkels, Johan Koekkoek, Maaike Vos, Linda Dirven, Martin Taphoorn
Journal: Neuro-Oncology (2020)

Abstract BACKGROUND The aim of this study was to explore the impact of the timing of health-related quality of life (HRQoL) measurements in clinical care on obtained HRQoL scores in glioma patients, and the association with feelings of anxiety or depression. METHODS Patients completed the EORTC Quality of Life Questionnaires (QLQ-C30 and QLQ-BN20), and the Hospital Anxiety and Depression Scale (HADS) at two time points. All patients completed the first measurement on the day of the MRI-scan (t=0), but the second measurement (t= 1) depended on randomization; group 1 (n= 49) completed the questionnaires before and group 2 (n= 51) after the consultation with the physician. RESULTS Median HRQoL scale/item scores on t0/t1 and change scores were comparable between the two groups. Between 8-58% of patients changed to a clinically relevant extent (i.e. ≥ 10 points) on the evaluated HRQoL scales/items in about one week time, in both directions, with only 3% of patients remaining stable in all scales. The mean number of the 26 evaluated HRQoL scales/items that changed to a clinically relevant extent per patient was 7 (SD= 4). Patients with stable role functioning had a lower HADS anxiety change score. However, this association was no longer significant in the multivariable regression when corrected for confounding factors. The HADS depression score was not associated with a change in HRQoL. DISCUSSION Measuring HRQoL before or after the consultation did not impact HRQoL scores on group level. However, the large majority of patients reported a clinically relevant difference in at least one HRQoL scale/item between the two time points, which was in general not influenced by feelings of anxiety or depression. Nevertheless, these findings highlight the importance of a standardized timing (e.g. at the day of the scan, consultation or first day of treatment) of patient-reported outcome assessments in clinical trials.
Agonist-antagonist myoneural interface amputation preserves proprioceptive sensorimotor neurophysiology in lower limbs
Authors: Shriya S. Srinivasan, Greta Tuckute, Jasmine Zou, Samantha Gutierrez-Arango, Hyungeun Song, Robert L. Barry, Hugh M. Herr
Journal: Science Translational Medicine (2020)

Agonist-antagonist myoneural interfaces in lower-limb amputation help preserve sensory feedback to the brain.
Preclinical Development of Virulence-attenuated <i>Streptococcus pneumoniae</i> Strains Able to Enhance Protective Immunity against Pneumococcal Infection
Authors: Elisa Ramos-Sevillano, Giuseppe Ercoli, Philip Felgner, Rafael Ramiro de Assis, Rie Nakajima, David Goldblatt, Robert S. Heyderman, Stephen B. Gordon, Daniela M. Ferreira, Jeremy S. Brown
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

"Preclinical Development of Virulence-attenuated Streptococcus pneumoniae Strains Able to Enhance Protective Immunity against Pneumococcal Infection." American Journal of Respiratory and Critical Care Medicine, 203(8), pp. 1037–1041
BIOM-19. METABOLIC ALTERATION INDUCED BY SELECTIVE KNOCK DOWN OF GABPB1L IN U251 CELLS
Authors: Noriaki Minami, Vinay Ayyappan, Nick Stevers, Abigail Molloy, Georgios Batsios, Donghyun Hong, Anne Marie Gillespie, Elavarasan Subramani, Marina Radoul, Joseph Costello, Pavithra Viswanath, Sabrina Ronen
Journal: Neuro-Oncology (2020)

Abstract BACKGROUND TERT promoter mutations that result in TERT expression are observed in over 80% of GBM and upstream inhibition of TERT expression by targeting GABPB1L is currently under investigation. In that context, non-invasive reliable biomarkers that can help detect TERT expression are needed. The aim of this research was to assess the value of magnetic resonance spectroscopy (MRS)-detectable metabolic changes as biomarkers of TERT expression in GBM. METHODS GABPB1L knock down clones (GABPB1LKD) were established by introducing Crispr Cas9 plasmid vector targeting GABPB1L into U251 cells. Two representative clones with different knock down efficiency were chosen and compared to control cells. Tumor forming capacity was evaluated by colony formation assay and magnetic resonance imaging of orthotopically implanted tumors in mice. Cells were extracted using the dual phase extraction method and 1H-MRS data of cell extracts acquired using a Bruker 500 scanner. The data was analyzed using Mnova software. Multivariate analysis was performed using the SIMCA software. RESULTS TERT expression was significantly reduced in GABPB1LKD compared to control cells depending on the GABPB1L knock down efficiency. Colony forming capacity was impaired in GABPB1LKD compared to control cells. In vivo MRI data showed significantly smaller tumor volumes in GABPB1LKD compared to control. Unbiased PCA analysis of 1H-MRS data showed separation of GABPB1LKD and control extracts and VIP scores derived from the OPLS-DA analysis, demonstrated that the common metabolites leading to separation of GABPB1LKD and control cells were aspartate, glutathione, glycerophosphocholine, glutamine, NAD(P)+, AXP. This data was confirmed by univariate analysis that revealed that aspartate, glutathione, glutamine, NAD(P)+, AXP level was significantly reduced in GABPB1LKD. CONCLUSIONS GABPB1L knock down cells that show reduced TERT expression demonstrate MRS-detectable metabolic changes. These could be translated into clinical applications, improve the monitoring of GBM patients and advance precision medicine.
Enhanced recovery after low- and medium-risk liver transplantation. A single-center prospective observational cohort study
Authors: Gonzalo P. Rodríguez-Laiz, Paola Melgar, Cándido Alcázar-López, Mariano Franco-Campello, Francisco Martínez-Adsuar, José Navarro-Martínez, Luís Gómez-Salinas, Sonia Pascual, Pau Bellot, Fernando Carnicer, María Rodríguez-Soler, José M. Palazón, Patricio Mas-Serrano, Susana Almanza-López, Francisco Jaime-Sánchez, Miguel Perdiguero, Carlos de Santiago, Teresa Lozano, Javier Irurzun, Enrique Pérez, Esperanza Merino, Pedro Zapater, Félix Lluís
Journal: International Journal of Surgery (2020)
COVD-17. TUMOR TREATING FIELDS FOR GLIOBLASTOMA THERAPY DURING THE COVID-19 PANDEMIC: EXPERT CONSENSUS ON USE AND EXPERIENCE
Authors: Na Tosha Gatson, Jill S Barnholtz-Sloan, Jan Drappatz, Roger Henriksson, Andreas Hottinger, Piet Hinoul, Carol Kruchko, Vinay Puduvalli, David Tran, Eric Wong, Martin Glas
Journal: Neuro-Oncology (2020)

Abstract BACKGROUND The COVID-19 pandemic has placed excessive strain on health care systems and this is especially evident in treatment decision-making for cancer patients. Glioblastoma (GBM) patients are among the most vulnerable due to increased incidence in the elderly (median age 64 years, peak between 75–84 years) and the short survival time. A virtual meeting was convened on May 9, 2020 with a panel of international neuro-oncology experts with hands-on experience using Tumor Treating Fields (TTFields). The objective was to assess the risk-to-benefit and to provide guidance for using TTFields in GBM during the COVID-19 pandemic. PANEL DISCUSSION Topics discussed included support and delivery of TTFields during the COVID-19 pandemic, concomitant use of TTFields with chemotherapy, and any potential impact of TTFields on the immune system in an intrinsically immunosuppressed GBM population. Special consideration was given to TTFields’ use in elderly patients and in combination with radiotherapy regimens (standard versus hypo-fractionated). Finally, we discussed the need to better capture COVID-19 positive brain tumor patients to analyze longitudinal outcomes and subtle changes in treatment decision-making during the pandemic. EXPERT CONSENSUS TTFields is a portable home-use device which can be managed via telemedicine and safely used in GBM patients during the COVID-19 pandemic. TTFields has no known immunosuppressive effects and is a reliable treatment modality with a relatively favorable side-effect profile. This is important during a crisis where other treatment methods might be limited, especially for elderly patients and patients with multiple co-morbidities. It is too early to estimate the full impact of COVID-19 on the global healthcare system and on patient outcomes and strongly recommended the need to collaborate with existing cancer COVID-19 registries (i.e. CCC19, ESMO-CoCARE, etc.) to follow CNS tumor patients. These efforts would have implications in assessing lessons-learned from this crisis and future guideline development.
More Progression Toward Regression?: Beyond Low-Density Lipoprotein Cholesterol Lowering**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Basil S. Lewis, David A. Halon
Journal: Journal of the American College of Cardiology (2010)
IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
Authors: Sabine Mueller, Jared Taitt, Erin Bonner, Rishi Lulla, Stewart Goldman, Anu Banerjee, Susan Chi, Nicholas S Whipple, John Crawford, Karen Gauvain, Kellie Nazemi, Payal Watchmaker, Takahide Nejo, Kaori Okada, Lisa H Butterfield, Javad Nazarian, Javier Villaneuva-Meyer, Annette M Molinaro, Michael Prados, Hideho Okada
Journal: Neuro-Oncology (2020)

Abstract OBJECTIVE To assess safety and efficacy within a multi-center trial the H3.3K27M specific peptide vaccine with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ DMGs. METHODS After focal radiation therapy, participants 3–21 years of age were enrolled into two strata. Stratum A: newly diagnosed diffuse intrinsic pontine glioma (DIPG); Stratum B: other DMGs. H3.3K27M vaccine was administered with poly-ICLC IM every 3 weeks for 8 doses followed by every 6 weeks for a total of 96 weeks. Immuno-monitoring of peripheral blood mononuclear cell (PBMC) and imaging occurred every 3 months. Modified iRANO criteria were applied. PBMC samples were evaluated by mass cytometry. RESULTS From November 2016 until March 2019, 19 eligible patients (median age 11, range 5–17 yrs; 53 % female) were enrolled in Stratum A and 10 eligible patients (median age 13, range 7–18 yrs; 60 % female) in Stratum B. Treatment was well tolerated (7 grade 3; 0 grade 4 related toxicities). Median number of vaccines per participant was 6 (range 1–11). Overall survival at 12 months was 40% (95% CI 22–73%) for Stratum A and 39% (95% CI 16–93%) for Stratum B. Among the 19 subjects with longitudinal immune cell assessments, 7 exhibited an expansion of K27M-reactive CD8+ effector memory T-cells correlating with prolonged survival (p=0.028). CONCLUSION H3.3K27M specific vaccine in combination with poly-ICLC is well tolerated. CyTOF-based immune monitoring of PBMCs facilitates sensitive high-throughput analysis. Further investigation is warranted to determine if this may be predictive of clinical outcomes.
Abstract P563: Association of Regularly Skipping Meals With Employees’ Workplace Food Choices and Overall Dietary Quality
Authors: Jessica L McCurley, Douglas E Levy, Hassan S Dashti, Eric B Rimm, Emily D Gelsomin, Anne N Thorndike
Journal: Circulation (2020)

Introduction: Breakfast skipping has been associated with poor diet, obesity, and risk of diabetes, but less is known about skipping lunch and dinner. We hypothesized that regular meal skipping by employees is associated with less healthy workplace food purchases, poorer dietary quality, and higher body mass index (BMI). Methods: This is a secondary analysis of baseline data from 602 hospital employees who regularly purchased from workplace cafeterias and enrolled in a workplace health promotion study in 2016-18. Hospital cafeterias used traffic-light labels (green = healthy, yellow = less healthy, red = unhealthy) for all foods. We calculated a Healthy Purchasing Score (HPS) using 3 months of employees’ purchases and weighting the proportion of items purchased (red=0, yellow=0.5, green=1; range 0-1, higher=healthier purchases). Healthy Eating Index (HEI; range 0-100, higher=healthier diet) was estimated using 24-hour dietary recalls. Meal skipping frequency was self-reported via questionnaire. Linear regression analyses examined differences in HPS, HEI, and BMI by meal skipping frequency (never skip, 1-2 days/week, 3+days/week), adjusting for age, sex, race, ethnicity, education, job type, shift work, marital status, and number of purchases. Results: Participants’ mean age was 43.6 years; 79% (N=478) were female and 81% (N=488) white. Mean BMI was 28.3 kg/m 2 (SD: 6.5), and 63% (N=377) were overweight/obese. Mean number of items purchased was 146 (SD: 71); mean HPS was .69 (SD .14) and mean HEI was 60.4 (SD: 12.5). The table shows that frequent meal skippi was associated with less healthy purchases at work, and breakfast skipping was associated with lower dietary quality. Meal skipping was not associated with BMI. Conclusions: Employees who skipped meals purchased less healthy food at work and breakfast skippers had poorer overall dietary intake. Results suggest that meal skipping may be an important factor in unhealthy eating habits of employees and should be considered in workplace health promotion efforts.
Abstract 13368: Hyperglycemia Inhibits Sirt1 Expression to Promote Drp1-Mediated Mitochondrial Fission in Diabetic Hearts
Authors: Mingge Ding, Jiahao Feng, Lang Hu, Min Jia, Zhenhua Liu, Feng Fu
Journal: Circulation (2018)

Introduction: Increased mitochondrial fission is involved in diabetic cardiomyopathy, but the underlying mechanisms are poorly understood. This study was designed to determine the role of SIRT1 in ...
AB0081 Central nervous system involvement in connective tissue diseases – our expirience
Authors: DZ Stefanovic, BC Glisic, MM Cirkovic, ZV Andjlekovic, MR Petronijevic, DV Mitrovic, MM Popovic
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Central nervous system involvements are the most severe clinical manifestations in connective tissue diseases. <h3>Objectives</h3> We estimated prevalence of central nervous system (CNS) involvement in our patients. <h3>Methods</h3> They were followed up during ten years period. <h3>Results</h3> Among 250 patients with systemic lupus erythematosus (SLE), 17 (7%) had alterations of CNS: cerebrovascular insult (5 pts), seizures (4 pts), psychosis (3 pts), transversal myelitis (2 pts), cranial nerve paralysis (2 pts) and psychoorganic syndrome (1 pt). In 3 pts SLE expressed primarily with CNS manifestations. Thirteen patients of 64 (20%) with Behcet disease had impairment of CNS: aseptic meningoencephalitis (2 pts), pyramid syndrome (2 pts), cerebelar-ataxic syndrome (2 pts), myelopathy (2 pts), cranial nerve paralysis (2 pts), psychosis (1 pt), cerebrovascular insult (1 pt) and idiopathic intracranial hypertension (1 pt). Only two patients of 50 with primary Sjogren syndrome expressed CNS manifestations as cranial nerve paralysis or disseminated demyelinisation disease. We also analysed our 20 patients with primary antiphospholipid syndrome, that is not connective tissue disease, but its immunological-mediated pathogenesis may affects functions of CNS. Among them two patients had multiinfarct dementia. <h3>Conclusion</h3> We concluded that CNS involvement is not frequent manifestation in our patients with connective tissue diseases.
Dying Poor in the US—Disparities in End-of-Life Care
Authors: Melissa W. Wachterman, Benjamin D. Sommers
Journal: JAMA (2021)

Dio Kavalieratos, PhD; Jennifer Corbelli, MD, MS; Di Zhang, BS; J. Nicholas Dionne-Odom, PhD, RN; Natalie C. Ernecoff, MPH; Janel Hanmer, MD, PhD; Zachariah P. Hoydich, BS; Dara Z. Ikejiani; Michele Klein-Fedyshin, MSLS, BSN, RN, BA; Camilla Zimmermann, MD, PhD; Sally C. Morton, PhD; Robert M. Arnold, MD; Lucas Heller, MD; Yael Schenker, MD, MAS
Применение показателей вариабельности сердечного ритма для оценки адаптационных процессов и уровня стресса у гастроэнтерологических больных (использование современных технологий PRECISE-диагностики)
Authors: Yu.M. Stepanov, E.V. Zyhalo
Journal: GASTROENTEROLOGY (2020)

Изучению вариабельности сердечного ритма (ВСР) посвящено множество научных работ. В статье приведен обзор публикаций по данной теме, где изложены современные представления о ВСР, по показателям которой можно оценить состояние механизмов регуляции физиологических функций организма человека, рассмотрены классические методы анализа и возможности клинического применения. Сердечный ритм является индикатором отклонений в вегетативном гомеостазе, причем изменение сердечного ритма — наиболее ранний прогностический признак возникновения многих заболеваний. В клинической практике анализ ВСР находит все более широкое применение при гастроэнтерологической патологии (гастроэзофагеальная рефлюксная болезнь, язвенная болезнь, синдром раздраженного кишечника), взаимодействии звеньев вегетативной нервной системы при различной гастроэнтерологической патологии. В ГУ «Институт гастроэнтерологии НАМН Украины» пациентов с разнообразной патологией пищеварительной системы обследуют при помощи современной PRECISE-диагностики для определения адаптационных и вегетативных нарушений с последующим лечением, используя технологии виртуальной реальности. С помощью PRECISE-диагностики анализируют уровень стресса и определяют возможный риск возникновения осложнений у гастроэнтерологических больных. Проводится анализ ВСР с использованием облачной технологии автоматизированной интерпретации электрокардиограммы с анализом более 700 параметров на основе Миннесотского кода с анализом каждого миллиметра сигнала.
MBRS-64. STUDY OF ARGININE METHYL TRANSFERASES IN MEDULLOBLASTOMA
Authors: Donghang Cheng, Pete Taylor, Monica Gireud, Shinji Maegawa, Yanwen Yang, Sadhan Majumder, Vidya Gopalakrishnan
Journal: Neuro-Oncology (2020)

Abstract Medulloblastoma is the most common malignant pediatric cancer and a leading cause of childhood cancer-related mortality. There is dire need for new therapies. Molecular sub-classification of medulloblastomas has identified chromatin modifiers as potential drivers of tumorigenesis. Expression of the RE1 Silencing Transcription Factor (REST), a hub for assembly of repressive chromatin remodelers and a known regulator of neurogenesis, is elevated in a subset of human sonic hedgehog (SHH) subgroup medulloblastomas, and is associated with poor prognosis. Using a novel transgenic mouse model, we showed REST to be a driver of medulloblastoma development. Surprisingly, our studies also revealed a role for REST in promoting proliferation of granule cell progenitors (GCPs), the cells of origin of SHH-driven medulloblastoma, and a concomitant loss of telomeres and increased genomic instability. We performed a gain of function screen using a library of chromatin modifiers to understand the mechanism by which proliferative potential was maintained, despite the loss of telomeres. This screen identified the Protein Arginine Methyltransferase 6 (PRMT6) as a high confidence hit. PRMT6 upregulation caused a reduction in CDKN2A, an important regulator of replicative senescence. Evasion of senescence is frequently implicated in tumor progression. Using a chemical screen, we also identified a novel, selective, reversible and competitive inhibitor of PRMT6. The consequence of genetic and pharmacological inhibition of PRMT6 on cell proliferation and senescence will be reported. Thus, our studies are the first to demonstrate a role for arginine methyl transferase family of chromatin modifiers in medulloblastoma genesis.
NURS-09. INTRODUCTION OF A WELLNESS PROGRAM FOR PEDIATRIC NEURO-ONCOLOGY PROVIDERS
Authors: Kaaren Waters, Helene Morgan, Kasey Rangan, Kim Bira, Tom Davidson, Nathan Robison, Ashley Margol
Journal: Neuro-Oncology (2020)

Abstract INTRODUCTION Pediatric oncology providers have unique and rewarding careers. The medical and psychosocial complexity of caring for pediatric oncology patients and their family units is simultaneously inspiring and challenging. In addition, the complex demands of the healthcare system can lead to chronic stress, burnout, and disruption to the healthcare professional’s individual well-being. Time constraints, lack of resources, and limited access to wellness interventions serve as barriers for providers to address adaptive coping within themselves. Identifying gaps to achieving wellness and implementing interventions may lead to improved equanimity for pediatric oncology providers in their personal lives as well as their medical practice. METHODS An interdisciplinary team of nurse practitioners and physicians in a large pediatric neuro-oncology program at an academic institution completed anonymized wellness self-assessments regarding the areas of emotional, environmental, intellectual, occupational, physical, social, spiritual, coping, and professional role wellness. The results were analyzed and barriers to provider health and well-being were identified. Tailored and regularly scheduled wellness interventions were implemented for the study participants addressing the identified wellness barriers. Participants will each complete post-intervention wellness self-assessments to evaluate the effectiveness of the program. CONCLUSION The introduction of a provider wellness program exemplifies a feasible approach to identify barriers and evaluate efficacy of wellness interventions in achieving multi-factorial provider wellness. Secondary aims include dissemination of findings, with the intention of cultivating improvement in provider quality of life throughout the healthcare profession, and the ultimate goal of improving care to patients and families.
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Authors: Catherine M. Otto, Rick A. Nishimura, Robert O. Bonow, Blase A. Carabello, John P. Erwin, Federico Gentile, Hani Jneid, Eric V. Krieger, Michael Mack, Christopher McLeod, Patrick T. O’Gara, Vera H. Rigolin, Thoralf M. Sundt, Annemarie Thompson, Christopher Toly
Journal: Circulation (2020)

Aim: This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use. Methods: A comprehensive literature search was conducted from January 1, 2010, to March 1, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, Cochrane, Agency for Healthcare Research and Quality Reports, and other selected database relevant to this guideline. Structure: Many recommendations from the earlier valvular heart disease guidelines have been updated with new evidence and provides newer options for diagnosis and treatment of valvular heart disease. This summary includes only the recommendations from the full guideline which focus on diagnostic work-up, the timing and choice of surgical and catheter interventions, and recommendations for medical therapy. The reader is referred to the full guideline for graphical flow charts, text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in developing these guidelines.